Reviewing ASLAN Pharmaceuticals (NASDAQ:ASLN) & Telomir Pharmaceuticals (NASDAQ:TELO)

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Earnings & Valuation

This table compares ASLAN Pharmaceuticals and Telomir Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12.00 million	0.10	-$44.22 million	($21.92)	-0.03
Telomir Pharmaceuticals	N/A	N/A	-$16.53 million	($0.58)	-4.29

Telomir Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ASLAN Pharmaceuticals and Telomir Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Telomir Pharmaceuticals	N/A	-1,170.58%	-832.67%

Volatility & Risk

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for ASLAN Pharmaceuticals and Telomir Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0	0	0	0	0.00
Telomir Pharmaceuticals	0	0	1	1	3.50

Telomir Pharmaceuticals has a consensus target price of $15.00, suggesting a potential upside of 502.41%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than ASLAN Pharmaceuticals.

Insider & Institutional Ownership

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Telomir Pharmaceuticals beats ASLAN Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.